Undisclosed aaRS-targeting program(s)
Oncology
Pre-clinicalActive
Key Facts
About Oxford Drug Design
Oxford Drug Design is a private, pre-clinical stage biotech with a distinctive dual-platform strategy combining deep biological expertise in tRNA synthetases (aaRS) with a proprietary AI/ML computational discovery engine. This integrated approach is applied to identify novel disease targets and advance drug candidates, with a current pipeline focused on oncology. The company operates from its Oxford, UK headquarters and appears to be pre-revenue, relying on investment and partnerships to fund its research and development activities. Its core proposition is the acceleration of drug discovery through a targeted, AI-powered platform against a validated but underexplored enzyme family.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |
| POLQ & eIF4E Assay | Aurora Biolabs | Commercial |
| PKMYT1 & WEE1 Assay | Aurora Biolabs | Commercial |
| NTP42 | ATXA Therapeutics | Preclinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Athebio | Pre-clinical |
| Dual-Targeting CAR-T Programs | Factor Bioscience | Pre-clinical |